Rolipram impairs NF-kappaB activity and MMP-9 expression in experimental autoimmune encephalomyelitis

Area of Science:

• Neuroimmunology
• Molecular Biology
• Pharmacology

Background:

• Experimental autoimmune encephalomyelitis (EAE) is a model for multiple sclerosis.
• Cell infiltration into the central nervous system (CNS) is a hallmark of EAE.
• Matrix metalloproteinase-9 (MMP-9) and nuclear factor-kappaB (NF-kappaB) are implicated in EAE pathogenesis.

Purpose of the Study:

• To investigate the mechanisms by which rolipram suppresses EAE.
• To determine the effects of rolipram on MMP-9 and NF-kappaB pathways in EAE.
• To assess rolipram's impact on immune cell migration.

Main Methods:

• Rolipram treatment in Lewis rats with EAE.
• Measurement of MMP-9 gene expression in lymph node cells (LNCs) and spinal cord.
• Assessment of NF-kappaB levels and translocation in LNCs.
• Luciferase reporter assays for NF-kappaB activity.
• Cell migration assays using a myelin basic protein (MBP) specific cell line.

Main Results:

• Rolipram suppressed EAE and reduced CNS cell infiltration.
• Rolipram decreased MMP-9 gene expression and NF-kappaB activity in LNCs and spinal cord.
• Impaired NF-kappaB translocation and reduced luciferase activity were observed.
• Rolipram diminished the migratory capacity of an MBP-specific cell line.
• IL-2 induced MMP-9 activity was only slightly affected.

Conclusions:

• Rolipram exerts its immunosuppressive effects in EAE by inhibiting MMP-9 and NF-kappaB pathways.
• These molecular changes correlate with reduced immune cell infiltration and migration.
• While rolipram impacts key inflammatory mediators, other factors may also contribute to its therapeutic action in EAE.